Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
Returns on capital
Context Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.7%
avg -52.4%
ROIC
-65.5%
avg -3.4%
ROA
-52.7%
avg -171.5%
Analysis
ROA is currently the strongest return metric at -52.7% versus its period average of -171.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director | USD 914.02K | 42 | 815.00K | 0.89% |
Jennifer Minai-Azary | Chief Financial Officer & Treasurer | USD 610.73K | 48 | — | — |
Alex C. Levit | Chief Legal Officer & Corporate Secretary | USD 576.31K | 47 | 270.00K | 0.29% |
Karen Chagin | Chief Medical Officer | USD 26.61K | 49 | — | — |
Jennifer Dashnau | Senior Vice President of Technical Operations | — | — | — | — |
Christopher Beck | Senior Vice President of Operations | — | — | — | — |
Jeffrey Liebman | Associate Director of Accounting | — | — | — | — |
Compensation is shown in the reported currency; data updated Jul 25, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 19, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Context Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CNTX's management, answered from reported figures.
Who manages CNTX?
Context Therapeutics Inc. (CNTX) lists 7 active executives. The top listed executive is Jennifer Minai-Azary, Chief Financial Officer & Treasurer.
Are CNTX insiders buying or selling?
Recent insider activity shows net buying of $8.75M.
Continue the stock analysis
Jump to another research area for this company.